Published in Acta Oncol on January 01, 2000
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
[Treatment of spinal cord compression caused by malignant disease]. Tidsskr Nor Laegeforen (1991) 2.04
[Treatment with growth factors and cytokines in hematologic diseases]. Tidsskr Nor Laegeforen (1996) 2.03
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines. Bone Marrow Transplant (2001) 1.66
Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol (2001) 1.49
Clinical stage I and II Hodgkin's disease: long-term results of therapy without laparotomy. Experience at one institution. Ann Oncol (1996) 1.45
Persistent changes in the immune system 4-10 years after ABMT. Bone Marrow Transplant (1999) 1.44
[High-dose autologous stem cell support in malignant diseases--an established method, uncertain indication]. Tidsskr Nor Laegeforen (1994) 1.39
Follow-up of breast cancer patients stage I-II: a baseline strategy. Eur J Cancer (1993) 1.39
Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol (2002) 1.37
Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. J Clin Oncol (1993) 1.35
Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. Eur J Cancer (2000) 1.29
A prospective study of health-related quality of life, fatigue, anxiety and depression 3-5 years after stem cell transplantation. Bone Marrow Transplant (2004) 1.14
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separation. Eur J Immunol (1990) 1.08
Extramedullary plasmacytomas and solitary plasma cell tumours of bone. Eur J Haematol (1990) 1.07
Valvular dysfunction and left ventricular changes in Hodgkin's lymphoma survivors. A longitudinal study. Br J Cancer (2009) 1.06
Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway. Eur J Cancer (2004) 1.05
Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart (1996) 1.03
Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human B lymphocytes. Exp Cell Res (1987) 1.02
Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol (2002) 1.02
High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage (2000) 0.96
A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer (1990) 0.96
3H-thymidine uptake in B cell lymphomas--relationship to treatment response and survival. Scand J Haematol (1985) 0.96
High incidence of serious side effects of high-dose dexamethasone treatment in patients with epidural spinal cord compression. J Neurooncol (1992) 0.95
Cardiopulmonary sequelae after treatment for Hodgkin's disease: increased risk in females? Ann Oncol (1996) 0.95
T-zone lymphoma with predominance of 'plasmacytoid T-cells' associated with myelomonocytic leukaemia--a distinct clinicopathological entity. J Pathol (1986) 0.94
Post-treatment parenthood in Hodgkin's lymphoma survivors. Br J Cancer (2007) 0.94
Spontaneous (H)-thymidine uptake in histological subgroups of human B-cell lymphomas. Scand J Haematol (1981) 0.93
Treatment of Burkitt's/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol (2004) 0.93
Immunological subsets in human B-cell lymphomas. Scand J Immunol (1981) 0.93
Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas. Int J Cancer (1984) 0.92
Health-related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial. Med Oncol (2001) 0.92
Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma. Int J Cancer (1989) 0.91
Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant (2005) 0.91
Late medical complications and fatigue in Hodgkin's disease survivors. J Clin Oncol (2001) 0.89
Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. Int J Cancer (2000) 0.89
Hodgkin's disease in a national and hospital population: trends over 20 years. Eur J Cancer (1997) 0.89
Do patients who are treated with stem cell transplantation have a health-related quality of life comparable to the general population after 1 year? Bone Marrow Transplant (1999) 0.88
Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. Eur J Cancer Clin Oncol (1986) 0.87
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol (2007) 0.87
High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant (2001) 0.87
Cellular antitumor immune response in women with risk factors for breast cancer. Cancer Res (1979) 0.87
Effects of benzaldehyde on survival and cell-cycle kinetics of human cells cultivated in vitro. Eur J Cancer Clin Oncol (1983) 0.87
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study. Ann Hematol (2004) 0.87
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol (2007) 0.86
Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods. Am J Pathol (1992) 0.86
Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway. Support Care Cancer (2004) 0.86
CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. Ann Oncol (1999) 0.86
Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemother Pharmacol (1999) 0.86
Erdheim-Chester disease: case with chronic discharging sinus from bone. AJR Am J Roentgenol (1980) 0.86
Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur J Cancer (1998) 0.85
A 10-year experience with splenectomy in patients with malignant non-Hodgkin's lymphoma at the Norwegian Radium Hospital. Cancer (1994) 0.84
Inhibition of polyphosphoinositide breakdown and c-myc induction accompanying inhibition of human B-cell activation by two monoclonal antibodies against the leucocyte common antigen (CD45). Scand J Immunol (1990) 0.84
Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol (2004) 0.84
Entourage: the immune microenvironment following follicular lymphoma. Blood Cancer J (2012) 0.83
Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma. J Neurooncol (1998) 0.83
A population-based study of spinal metastatic disease in South-East Norway. Clin Oncol (R Coll Radiol) (2009) 0.83
ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma--the Nordic Lymphoma Group experience. Eur J Haematol (2004) 0.83
Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy. Br J Cancer (2009) 0.83
c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell non-Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization. Cytometry (1999) 0.83
Loss of chromosome 11q21-23.1 and 17p and gain of chromosome 6p are independent prognostic indicators in B-cell non-Hodgkin's lymphoma. Br J Cancer (2001) 0.83
Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells. J Immunol (1987) 0.83
Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas. Leukemia (2006) 0.83
Cell-associated immunoglobulin in human non-Hodgkin lymphomas. A comparative study of surface immunoglobulin on cells in suspension and cytoplasmic immunoglobulin by immunohistochemistry. Acta Pathol Microbiol Scand A (1981) 0.83
Demecolcin and vinblastine sulphate as stathmokinetic agents for different tissues of the hairless mouse. Pathol Eur (1975) 0.82
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2012) 0.81
Simultaneous assessment of chromatin structure, DNA content, and antigen expression by dual wavelength excitation flow cytometry. Cytometry (1991) 0.81
Tissue specificity of the epidermal chalones. Virchows Arch B Cell Pathol (1975) 0.81
CD34(+) cell enrichment depletes atypical CD30(+) cells from PBPC grafts in patients with HD. Cytotherapy (2001) 0.81
Lung function impairment in long-term survivors of Hodgkin's disease. Ann Oncol (1995) 0.81
High-dose therapy in patients with Hodgkin's disease: the use of selected CD34(+) cells is as safe as unmanipulated peripheral blood progenitor cells. Bone Marrow Transplant (2001) 0.80
Downregulation of c-myc RNA is not a prerequisite for reduced cell proliferation, but is associated with G1 arrest in B-lymphoid cell lines. Exp Cell Res (1987) 0.80
[Diagnosis and treatment of solitary plasmacytoma]. Tidsskr Nor Laegeforen (1990) 0.80
The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas. Int J Cancer (1987) 0.80
Late medical sequelae after therapy for supradiaphragmatic Hodgkin's disease. Acta Oncol (1999) 0.80